Group 1 - Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - Jefferies downgraded First Solar from Buy to Hold on January 7, 2026, citing lowered guidance, significant de-bookings, and margin compression throughout 2025 [2] - Following the downgrade, First Solar's stock price decreased by $27.67, or 10.29%, closing at $241.11 per share on January 7, 2026 [2] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - AST SpaceMobile, Inc. is under investigation for potential securities fraud and unlawful business practices, coinciding with a recent downgrade by Scotiabank which has negatively impacted the company's stock price [1][2]. Group 1: Company Investigation - Pomerantz LLP is investigating claims on behalf of investors of AST SpaceMobile, Inc. regarding possible securities fraud or other unlawful business practices by the company and its officers [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance and Analyst Downgrade - On January 7, 2026, Scotiabank downgraded AST SpaceMobile to a "Sell" rating, citing significant competition from SpaceX's Starlink, slow customer adoption, and delays in launching AST's satellites [2]. - Following the downgrade, AST's stock price decreased by $11.76 per share, representing a 12.06% decline, closing at $85.73 per share on the same day [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Instil Bio, Inc. and its officers or directors [1] Group 1: Company Developments - On January 6, 2026, Instil announced that its subsidiary, Axion Bio, Inc., will discontinue the clinical development of AXN-2510 and terminate its collaboration agreement with ImmuneOnco Biopharmaceuticals [2] - Following this announcement, Instil's stock price dropped by $5.63 per share, representing a decline of 45.81%, closing at $6.66 per share on the same day [2] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Bgin Blockchain Limited and its officers or directors [1] Financial Performance - Bgin reported a significant decline in total revenue of approximately $96 million for the six months ending June 30, 2025, compared to the previous year [2] - Operating expenses surged by 582.8%, indicating severe financial strain [2] - The company's gross profit fell from $84.8 million in the prior year to a gross loss of $6.3 million [2] Management Changes - On December 5, 2025, Bgin announced the termination of its Chief Communications Officer's employment on a mutual basis [2] - On December 15, 2025, Bgin decided not to renew its engagement with its current auditor and approved the hiring of a new independent registered public accounting firm effective December 12, 2025 [2] Stock Performance - As of December 29, 2025, Bgin's stock closed at $2.45, which is below its initial public offering (IPO) price [2]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Ramaco Resources, Inc. and its officers and directors [1][2]. Group 1: Investigation Details - The investigation is prompted by allegations from Wolfpack Research that Ramaco's Brook Mine project is a "hoax" and that the company manipulated data to misrepresent its profitability [2]. - Following the allegations, Ramaco's stock price experienced a significant decline, falling by $3.81 per share, or 9.57%, closing at $36.01 per share on October 23, 2025 [2]. Group 2: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [2]. - The firm has successfully recovered numerous multimillion-dollar damages awards for class members [2].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations that Charming and certain officers and/or directors engaged in securities fraud [2]. - Investors have until February 17, 2026, to request to be appointed as Lead Plaintiff if they purchased Charming securities during the Class Period [2]. Group 2: Stock Performance and SEC Action - On November 11, 2025, Charming's stock closed at $29.36, with an intraday high of $31.70, and had approximately 17.18 million shares outstanding, resulting in a market capitalization of around $504 million [4]. - Following this, the SEC halted trading of Charming securities from November 12 through 25, 2025, due to allegations of price manipulation through social media, which was part of a "pump-and-dump" scheme [4].

Core Viewpoint - A class action lawsuit has been filed against Smartsheet Inc. regarding allegations of securities fraud and unlawful business practices related to a recent merger [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Smartsheet and certain officers and directors engaged in securities fraud during the solicitation of stockholder approval for a merger with investment funds managed by Blackstone, Vista Equity Partners, and others [4][5]. - Investors have until February 24, 2026, to request to be appointed as Lead Plaintiff if they purchased Smartsheet securities during the class period [2]. Group 2: Allegations Against Smartsheet - The complaint alleges that Smartsheet issued a misleading Schedule 14A Proxy statement to the U.S. Securities and Exchange Commission, mischaracterizing the company's financial performance to solicit approval for the merger [5]. - The Proxy allegedly presented the company's quarterly earnings negatively and emphasized a financial metric created specifically for the merger approval process [5]. Group 3: Financial Implications - The merger consideration was set at $56.50 per share, which was within the range of a discounted cash flow analysis but below several analyst price targets that had been raised following the company's successes in early 2024 [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers and directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Nutanix, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On November 25, 2025, Nutanix reported first-quarter fiscal year 2026 revenue that was near the lower end of its prior guidance, attributing this to a late quarter revenue shift due to increased customer demand for flexible start dates and growth through third-party OEM partners [3]. - The company revised its full-year revenue projection down from a range of $2.9 billion to $2.94 billion to a new range of $2.82 billion to $2.86 billion [3]. Stock Market Reaction - Following the announcement of the financial results, Nutanix's stock price fell by $10.43 per share, representing a 17.8% decline, closing at $48.34 per share on November 26, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zenas BioPharma, Inc. following a significant drop in stock price after the announcement of Phase 3 trial results for obexelimab [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is currently under investigation for possible securities fraud [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Financial Impact - Following the announcement of the trial results, Zenas's stock price decreased by $17.89 per share, representing a decline of 51.86%, closing at $16.61 per share on January 5, 2026 [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].